YellowLegalPad Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YellowLegalPad

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (1139)	9/17/2010 5:18:02 PM
From: John McCarthy	Read Replies (1) of 1182

RVX.TO Archie, you don't seem to be intentional uniformed but I not sure if your just a paid basher or geniunely have concerns Lets get you up to speed with this comment from BFW on another board If the just-released statin metadata study turns out to be accurate and if RVX's NexVas program turns out to deal with far more fundamental causes of CVD (reverse cholesetrol transport [RCT] and inflammation) then the NexVas program could produce drugs that supplant almost all current CVD treatments. We could be looking at sales of $30 billion per year and more. We may even be looking at near universally prescribed preventive treatment with this. Absolute monster in the waiting..." The metadata study showed no benefit for statins in primary prevention with regards to mortality. I'm sure the stats were done correctly so it has internal accuracy. I suspect it is valid as well as Nissen said ""Because mortality is low in primary-prevention patients, it is difficult to show a mortality benefit. This has been established previously. The primary benefit in this setting is reduction in nonfatal MI, which remains a worthwhile goal of therapy," So..the Jupiter study still stands out as for primary prevention... but they selected patient with high hsCRP levels so it was primary prevention in an "inflamed" group. The metadata study above took all comers. One would expect that RVX208's niche would be in focusing on either an inflamed group or a group with low HDL/low ApoA1. One might even postulate that they would have an easier time showing a benefit for RVX208 in a group of patients exhibiting both of the above characteristics. If I was designing the trials, I'd want to focus on those most likely to show a statistically significant benefit in the shortest period of time. Hopefully, RVX is using the ASSERT data in this manner to tweak the ASSURE trial. Furthermore, even if RVX208 only shows a benefit in a specific group prior to coming to market, one would suspect that the use of the medication would leak out in to primary prevention. messages.finance.yahoo.com CRACKER

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next